Disease | medullary thyroid carcinoma |
Comorbidity | C0027662|multiple endocrine neoplasia |
Sentences | 6 |
PubMedID- 22584721 | We briefly review the surgical approaches to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2 (medullary thyroid carcinoma/multiple endocrine neoplasia type 2). |
PubMedID- 22127824 | Thyroid neoplasia preclinical rodent studies with liraglutide have shown an increase in c-cell thyroid cancer, which so far has not been demonstrated in monkeys or humans.25 based on the preclinical studies in rodents, the fda has requested a boxed warning for liraglutide, which includes contraindications for use in “...patients with a personal or family history of medullary thyroid carcinoma (mtc) or in patients with multiple endocrine neoplasia syndrome type 2 (men 2).”25 recent findings from a large screening study in 5000 subjects treated with liraglutide did not support an effect of glp-1 receptor activation on serum calcitonin levels in humans, as reported in rodent studies.26 however, ongoing studies are evaluating the long-term safety of incretinbased therapy. |
PubMedID- 26487970 | Acute coronary syndrome: a rare case of multiple endocrine neoplasia syndromes with pheochromocytoma and medullary thyroid carcinoma. |
PubMedID- 23705087 | Sonographic findings of medullary thyroid carcinoma leading to diagnosis of multiple endocrine neoplasia type 2a during pregnancy. |
PubMedID- 23249377 | There were five benign thyroid conditions and four thyroid cancers, including three papillary thyroid cancers and one bilateral medullary thyroid cancer in a patient with multiple endocrine neoplasia 2a. |
PubMedID- 23979292 | Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2b: a changing perspective. |
Page: 1